Viking's Oral Obesity Drug Poised To Gain Ground After Eli Lilly's Orforglipron Setback: Analyst

Why did US wholesale prices surge in July? What impact do Trump’s tariffs have on inflation? How will the Intel stake talks affect its future? Why is Air Canada canceling flights now? What caused Tesla’s recent robotaxi push? How did Meta’s AI strategy spark employee tension? Why are investors worried about Trade Desk's growth?

Viking's Oral Obesity Drug Poised To Gain Ground After Eli Lilly's Orforglipron Setback: Analyst

benzinga.com/analyst-stock-ratings/analyst-color/25/08/47102552/vikings-oral-obesity-drug-poised-to-gain-ground-after-eli-lillys-orforglipron

Viking Therapeutics, Inc. (NASDAQ:VKTX) is pressing ahead in the weight-loss drug race with the launch of its Phase 2 VENTURE-Oral trial to test a daily pill version of VK2735 in obese and overweight adults, a move analysts say could position the company to capitalize on Eli Lilly’s…

This story appeared on benzinga.com, 2025-08-13 18:30:35.